B1680
Bradyzide di(trifluoroacetate) salt hydrate
≥98%
동의어(들):
(S)-1-[4-(4-Benzhydrylthiosemicarbazido)-3-nitrobenzenesulfonyl]-pyrrolidine-2-carboxylic acid [2-[(2-dimethylaminoethyl)methylamino]ethyl] amide
로그인조직 및 계약 가격 보기
모든 사진(1)
About This Item
실험식(Hill 표기법):
C32H42N8O5S2 · 2C2HF3O2 · xH2O
Molecular Weight:
910.90 (anhydrous basis)
MDL number:
UNSPSC 코드:
41106200
NACRES:
NA.32
추천 제품
생화학적/생리학적 작용
Potent, orally active, non-peptide B2 bradykinin receptor antagonist.
특징 및 장점
This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
개인 보호 장비
Eyeshields, Gloves, type N95 (US)
시험 성적서(COA)
제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.
G M Burgess et al.
British journal of pharmacology, 129(1), 77-86 (2000-02-29)
Bradyzide is from a novel class of rodent-selective non-peptide B(2) bradykinin antagonists (1-(2-Nitrophenyl)thiosemicarbazides). Bradyzide has high affinity for the rodent B(2) receptor, displacing [(3)H]-bradykinin binding in NG108-15 cells and in Cos-7 cells expressing the rat receptor with K(I) values of
Marielza Andrade Nunes et al.
Pharmaceuticals (Basel, Switzerland), 13(10) (2020-10-07)
Alzheimer's disease is mainly characterized by remarkable neurodegeneration in brain areas related to memory formation. This progressive neurodegeneration causes cognitive impairment, changes in behavior, functional disability, and even death. Our group has demonstrated changes in the kallikrein-kinin system (KKS) in
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.